136 related articles for article (PubMed ID: 3746020)
1. [Effect of immunotherapy using the non-specific immunopotentiator OK-432 in malignant ovarian tumors--selecting appropriate cases for immunotherapy].
Nishida Y; Sakakibara K; Kano T; Ohta M; Tomoda Y
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jul; 38(7):1017-25. PubMed ID: 3746020
[TBL] [Abstract][Full Text] [Related]
2. [Immunotherapy of terminal-stage malignant tumors with the immunopotentiator OK-432--a comparison between SU-PS test-responder and -nonresponder patients].
Yagi Y; Yagi S; Ichiki H
Gan No Rinsho; 1987 Jun; 33(7):815-21. PubMed ID: 3302349
[TBL] [Abstract][Full Text] [Related]
3. [Clinical significance of Su-polysaccharide (Su-PS) skin test in patients with primary lung cancer treated with chemotherapy and administration of OK-432, with special reference to the therapeutic effect and prognosis].
Horiuchi M; Sato K; Nakarai I; Shinoda A
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):468-74. PubMed ID: 2181937
[TBL] [Abstract][Full Text] [Related]
4. [Immunotherapy for lung cancer by streptococcal preparation OK-432].
Watanabe Y; Shimizu J; Yoshida Y; Hashizume Y; Yamada T; Iwa T
Nihon Geka Gakkai Zasshi; 1989 Sep; 90(9):1432-5. PubMed ID: 2586434
[TBL] [Abstract][Full Text] [Related]
5. Modulation of NK activity in regional lymph nodes by preoperative immunotherapy with OK-432 in patients with cancer of the oral cavity.
Vinzenz K; Matejka M; Watzek G; Porteder H; Neuhold N; Micksche M
Cancer Detect Prev Suppl; 1987; 1():463-75. PubMed ID: 3480060
[TBL] [Abstract][Full Text] [Related]
6. [Clinical significance of a skin test (SU-PS) for immune responses in patients with gastrointestinal cancer treated with OK-432].
Miyamoto Y; Takeshita M; Izuo M
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3229-35. PubMed ID: 3777960
[TBL] [Abstract][Full Text] [Related]
7. [The effect of OK-432 in the treatment of primary lung cancer].
Kishimoto T; Okada K
Gan To Kagaku Ryoho; 1987 Apr; 14(4):1051-6. PubMed ID: 3494430
[TBL] [Abstract][Full Text] [Related]
8. [Observation on natural killer cell activity in gastric cancer patients and effect of nonspecific immunopotentiator administration on its postoperative reduction].
Oshita H; Saji S; Sugiyama Y; Tanemura H; Sakata K; Tanaka S; Ito T
Nihon Geka Gakkai Zasshi; 1985 Oct; 86(10):1417-25. PubMed ID: 4079897
[TBL] [Abstract][Full Text] [Related]
9. [Experimental study on the antitumor activity of regional lymph nodes during immunotherapy].
Kawata H
Nihon Geka Gakkai Zasshi; 1984 Nov; 85(11):1479-89. PubMed ID: 6521727
[TBL] [Abstract][Full Text] [Related]
10. Effects of biological response modifier on thoracic duct lymphocytes in recurrent gastric cancer. Evaluation of OK-432, a hemolytic streptococcus preparation.
Hanaue H; Kim DY; Kubota M; Kurosawa T; Shikata J; Kondoh Y; Ogoshi K; Makuuchi H; Nakasaki H; Mitomi T
Tokai J Exp Clin Med; 1987 May; 12(2):97-102. PubMed ID: 3502432
[TBL] [Abstract][Full Text] [Related]
11. [Su-polysaccharide skin test and immunotherapy with OK-432 in postoperative gastric cancer--the effect of a splenectomy].
Saito H; Kikkawa H; Bando H; Sakatoku M; Hirano M; Tatsuzawa T
Gan No Rinsho; 1988 Nov; 34(14):1965-8. PubMed ID: 3204664
[TBL] [Abstract][Full Text] [Related]
12. [Role of immune skin reactions in progressive lung cancer during the administration of OK-432--relation to reactions to DNCB, PPD and Su-PS].
Katada H; Nishikawa K; Yoneda T; Kitamura H; Nakajima A; Mikami R
Gan To Kagaku Ryoho; 1987 Jan; 14(1):61-70. PubMed ID: 3026256
[TBL] [Abstract][Full Text] [Related]
13. [Adjuvant immunochemotherapy with long-term OK-432 administration in colorectal cancer].
Kikkawa N; Sasai H; Kawahara T
Gan To Kagaku Ryoho; 1984 Oct; 11(10):2163-9. PubMed ID: 6486832
[TBL] [Abstract][Full Text] [Related]
14. [Immunotherapy, with OK-432 for cases of nasopharyngeal carcinoma].
Tsukuda M; Tamamushi N; Mochimatsu I; Mitarai K; Kaneko M; Sawaki S
Gan To Kagaku Ryoho; 1986 Jan; 13(1):53-9. PubMed ID: 3942399
[TBL] [Abstract][Full Text] [Related]
15. [Role of the spleen in OK-432 immunotherapy and characterization of effector cells].
Yamagishi H; Naito K; Maeda Y; Kobayashi M; Kurioka H; Fujimori C; Tanaka T; Hashimoto I
Gan To Kagaku Ryoho; 1983 Jul; 10(7):1670-8. PubMed ID: 6870309
[TBL] [Abstract][Full Text] [Related]
16. [Studies of immunotherapy of malignant urogenital tumors: 2nd report. Changes in the K-cell population of the peripheral blood in patients with malignant tumors and the significance of antibody dependent cell-mediated cytotoxicity (ADCC) in OK-432 immunotherapy].
Fujioka T; Tanji S; Koike H; Suzuki K; Aoki H; Banya Y; Kubo T; Ohhori T
Nihon Hinyokika Gakkai Zasshi; 1987 Jan; 78(1):29-38. PubMed ID: 3599595
[No Abstract] [Full Text] [Related]
17. Effect of streptococcal lyzate OK-432 on peripheral blood mononuclear cells in gastric cancer patients.
Nakayama F; Iwagaki H; Gouchi A; Hizuta A; Isozaki H; Takakura N; Tanaka N
J Med; 1998; 29(3-4):199-215. PubMed ID: 9865458
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of patients with terminal-stage malignant tumors with an immunopotentiator OK-432--a comparison of SU-PS test-responding and -nonresponding patients.
Yagi Y; Yagi S
Int J Immunopharmacol; 1988; 10(4):451-61. PubMed ID: 3049405
[TBL] [Abstract][Full Text] [Related]
19. [Local immunotherapy with streptococcal preparation, OK-432 in superficial bladder tumors, and common antigens between OK-432 and the tumor].
Fujioka T; Shiraishi M; Tanji S; Koike H; Suzuki K; Kumagai K; Aoki H; Sakuma Y; Ohhori T; Kubo T
Hinyokika Kiyo; 1989 Feb; 35(2):253-7. PubMed ID: 2735236
[TBL] [Abstract][Full Text] [Related]
20. New approach to management of malignant ascites with streptococcal preparation OK-432. III. OK-432 attracts natural killer cells through a chemotactic factor released from activated neutrophils.
Hayashi Y; Torisu M
Surgery; 1990 Jan; 107(1):74-84. PubMed ID: 2404351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
